Abstract Library

#4599 Endosonography guided coloenterostomy for management of malignant small bowel ileus

Introduction: Small-bowel ileus (SBI) is often decisive for the prognosis in midgut neuroendocrine tumours (NET) and other peritoneally metastasised neoplasias. Conventional procedures of palliative care deliver unsatisfying results.

Conference:

Presenting Author: Weich A

Authors: Weich A, Retzbach L, Hartung V, Brand M, Kudlich T,

Keywords: Coloenterostomy, Endosonography, small bowel ileus, peritoneal carcinomatosis, midgut NET,

#4597 FIT-NETs: Assessing the effects of an exercise programme on the physical and emotional well-being of patients with advanced G1-2 NETs of GEP or unknown origin

Introduction: Physical activity programs in solid tumours have shown to improve symptom control and even survival, but their impact on NENs remains unexplored. Advanced disease, systemic therapy, and hormonal secretion in these tumours often lead to muscle wasting and sarcopenia.

Conference:

Presenting Author: Anton-Pascual B

Authors: Anton-Pascual B, Rodriguez-Gomez J, de Cima A, Herrero-Llorente A, Modrego A,

Keywords: FIT-NET, physical exercise program, Quadriceps, MEP & MIP, QoL,

#4576 Economic evidence for pancreatic and extra-pancreatic neuroendocrine tumours following treatment failure or disease progression: A systematic literature review

Introduction: Treatment failure and disease progression (PD) in neuroendocrine tumours (NETs), a rare group of malignancies, are common due to limited targeted treatments.

Conference:

Presenting Author:

Authors: Karim E, Sola-Morales O, Bensegnor H, Chan K, Drane E,

Keywords: Neuroendocrine Tumour, Systematic Literature Review, Economic,

#4529 Long-term quality of life after pancreatic surgery for neuroendocrine tumours of the pancreas: Outcome of 100 patients evaluated with new EORTC questionnaires

Introduction: Patients with Pancreatic Neuroendocrine Tumours (PanNETs) often have a good prognosis with long overall survival.

Conference:

Presenting Author: Milanetto A

Authors: Milanetto A, Armellin C, Veronese E, Lorenzoni G, Pasquali C,

Keywords: net, pancreatic, quality of life,

#4498 Quality of life outcome after each cycle in NET patients receiving peptide receptor radionuclide therapy (PRRT)

Introduction: Quality of Life (QoL) Questionnaire GI NET21 was developed specifically for neuroendocrine tumours (NET). A significant proportion of all patients with GEP-NETs will ultimately present with a wide variety of NET-related symptoms such as skin flushing, diarrhoea and pain as well as disease related worries that can reduce QoL. Peptide receptor radionuclide therapy (PRRT) is an established treatment in NETs and has been shown to extend survival. However, QoL data post PRRT is still somewhat limited.

Conference:

Presenting Author: Vito I

Authors: Vito I, Santillan N, Davis N, Navalkissoor S,

Keywords: Lu-177-DOTATATE, PRRT, Quality of Life,